Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2021-02-24

Clinical Trial Update: Biomarker Trial of Everolimus in Patients With Advanced Renal Cell Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 biomarker trial of everolimus in advanced renal cell carcinoma has completed; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Everolimus (everolimus)

Snippet

Sponsor: Beth Israel Deaconess Medical Center | Conditions: Renal Cell Carcinoma, Renal Cancer | Phase 2 | Status: COMPLETED | Results posted: 2021-02-24